Update on Cognitive Enhancers Among the Older Adult Population: A Clinical Review.

IF 5.5 2区医学 Q1 PSYCHIATRY

Current Psychiatry Reports Pub Date : 2024-03-01 Epub Date: 2024-02-21 DOI:10.1007/s11920-024-01484-6

Deanna Fernandes, Uma Suryadevara, Dawn Bruijnzeel, Josepha Cheong

{"title":"Update on Cognitive Enhancers Among the Older Adult Population: A Clinical Review.","authors":"Deanna Fernandes, Uma Suryadevara, Dawn Bruijnzeel, Josepha Cheong","doi":"10.1007/s11920-024-01484-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: The purpose of this review is to identify key classes of medications that are used for the treatment of older adults with neurocognitive disorders.Recent findings: Clinical factors play a critical role in the prescribing of these medication classes for the treatment of dementia. The variation in prescribing trends is determined by the presence of medical and psychiatric comorbidities commonly occurring in older adults and is based on the consideration of potential interactions between pharmacotherapies for the comorbidities and for the dementia. Six medication classes currently exist to address the neurocognitive aspect of dementia, with varying pharmacokinetic and pharmacodynamic profiles. We review these six classes in this report and provide a provision of clinical insights regarding the use of these agents. While literature exists on the safety and efficacy of individual medication options for the treatment of dementia in the older adult population, further research is needed to provide clearer guidance regarding the specific use of these agents in clinical practice.","PeriodicalId":11057,"journal":{"name":"Current Psychiatry Reports","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Psychiatry Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11920-024-01484-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The purpose of this review is to identify key classes of medications that are used for the treatment of older adults with neurocognitive disorders.

Recent findings: Clinical factors play a critical role in the prescribing of these medication classes for the treatment of dementia. The variation in prescribing trends is determined by the presence of medical and psychiatric comorbidities commonly occurring in older adults and is based on the consideration of potential interactions between pharmacotherapies for the comorbidities and for the dementia. Six medication classes currently exist to address the neurocognitive aspect of dementia, with varying pharmacokinetic and pharmacodynamic profiles. We review these six classes in this report and provide a provision of clinical insights regarding the use of these agents. While literature exists on the safety and efficacy of individual medication options for the treatment of dementia in the older adult population, further research is needed to provide clearer guidance regarding the specific use of these agents in clinical practice.

查看原文本刊更多论文

老年人群中认知增强剂的最新进展：临床回顾。

综述目的：本综述旨在确定用于治疗患有神经认知障碍的老年人的主要药物类别：临床因素在开具治疗痴呆症的药物处方中起着至关重要的作用。处方趋势的变化取决于是否存在老年人常见的内科和精神科合并症，并基于对合并症和痴呆症药物疗法之间潜在相互作用的考虑。目前有六类药物可用于治疗痴呆症的神经认知方面，它们的药代动力学和药效学特征各不相同。我们在本报告中回顾了这六类药物，并就这些药物的使用提供了临床见解。虽然已有文献介绍了用于治疗老年人痴呆症的各种药物的安全性和有效性，但仍需进一步研究，以便为这些药物在临床实践中的具体使用提供更明确的指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Psychiatry Reports PSYCHIATRY-

CiteScore

11.30

自引率

3.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published research in psychiatry. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by psychiatric disorders. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anxiety, medicopsychiatric disorders, and schizophrenia and other related psychotic disorders. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.